The purpose of this study is to determine whether sildenafil is effective and safe in the treatment of fetal growth restriction.
Fetal growth retardation affects up to 8% of all pregnancies and has massive short term (increased fetal morbidity and mortality) and long-term (increased incidence of cardiovascular disorders in adulthood) health implications. Doppler waveform analysis of these pregnancies suggests compromised uteroplacental circulation and placental hypoperfusion. Our aim is to assess if sildenafil citrate could improve vasodilatation in FGR pregnancies. Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental perfusion in FGR. Animal studies suggest that phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil citrate, may improve uterine blood flow .
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
70
50 mg TDS orally until birth
50mg tid
Tehran UMS
Tehran, Tehran Province, Iran
RECRUITINGUteroplacental Perfusion
Time frame: 2 hours after sildenafil ingestion
fetal growth
Time frame: after 6 months
umbilical artery blood gass assessment
Time frame: immediately after birth
effect on fetal well being
when BP score is\<8 we repeat it after sildenafil ingestion
Time frame: 2 hours after sildenafil
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.